Highlights Invex Therapeutics Ltd

Equities

IXC

AU0000048621

Market Closed - Australian S.E. Other stock markets 01:54:43 22/05/2024 BST			5-day change	1st Jan Change
0.084 ^AUD	+10.53%		+10.53%	+3.70%

03-20	Australia's Tax Agency Publishes Ruling on Invex Therapeutics' Capital Return	MT
02-16	Invex Therapeutics Narrows Fiscal H1 Loss on Lower R&D Expenses	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Australia's Tax Agency Publishes Ruling on Invex Therapeutics' Capital Return	03-20	MT
Invex Therapeutics Narrows Fiscal H1 Loss on Lower R&D Expenses	02-16	MT
Invex Therapeutics Ltd Reports Earnings Results for the Half Year Ended December 31, 2023	02-15	CI
Invex Therapeutics, Peptron End Collaboration, Manufacturing Deal	12-22	MT
Invex Therapeutics to Secure European Patent Grant for Neurological Medication	11-22	MT
Invex Therapeutics Ltd Reports Earnings Results for the Full Year Ended June 30, 2023	17/08/23	CI
Invex Therapeutics Ltd Announces Board Changes	03/07/23	CI
Invex Therapeutics Jumps 19% After Securing Second European Orphan Drug Designation for Exenatide	23/06/23	MT
Invex Therapeutics Secures Approval for IIH EVOLVE Phase III Trial in France; Shares Rise 7%	21/04/23	MT
Israel's Ministry of Health Approves Invex Therapeutics' IIH EVOLVE Clinical Trial	20/04/23	MT
Invex Therapeutics Secures Clearance for Phase 2 Neurological Trial in Germany; Shares Rise 4%	20/03/23	MT
Invex Therapeutics Ltd Announces the Approval to Commence the IIH EVOLVE Phase III Clinical Trial	19/03/23	CI
Invex Therapeutics Ltd. Announces the Publication of the Invex Phase II 'Pressure' Clinical Trial	13/03/23	CI
Invex Therapeutics More Than Doubles Fiscal H1 Loss	17/02/23	MT
Invex Therapeutics Ltd Reports Earnings Results for the Half Year Ended December 31, 2022	16/02/23	CI
Invex Therapeutics Ltd Announces First US Clinical Site Activated in IIH Evolve Phase III Clinical Trial	18/01/23	CI
Invex Therapeutics Gains European Regulator Approval for Pediatric Plan	14/12/22	MT
Invex Therapeutics Ltd Receives Approval for Paediatric Plan from the EMA	13/12/22	CI
Invex Therapeutics Secures Regulatory, Ethics Approval for Phase 3 Neurological Trial in New Zealand	25/11/22	MT
Invex Therapeutics Ltd Announces Approval to Commence the IIH EVOLVE Phase III Clinical Trial Received from the New Zealand Medicines and Medical Devices Safety Authority	24/11/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Invex Therapeutics Ltd

Equities

IXC

AU0000048621

Highlights

Filters